Skip to main content

A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (PASS)

Clinical Trial Grant
Duke Scholars

Administered By

Neurology, MS & Neuroimmunology

Awarded By

Genzyme Corporation

Start Date

November 18, 2016

End Date

December 31, 2028
 

Administered By

Neurology, MS & Neuroimmunology

Awarded By

Genzyme Corporation

Start Date

November 18, 2016

End Date

December 31, 2028